These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1240 related items for PubMed ID: 29205405

  • 1. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F, Schlevogt B, Deterding K, Wranke A, Smith A, Port K, Manns MP, Vogel A, Cornberg M, Wedemeyer H.
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [Abstract] [Full Text] [Related]

  • 2. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E, D'Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, Borghi M, Lunghi G, Colombo M, Lampertico P.
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [Abstract] [Full Text] [Related]

  • 3. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
    Yoo SH, Kwon JH, Nam SW, Kim HY, Kim CW, You CR, Choi SW, Cho SH, Han JY, Song DS, Chang UI, Yang JM, Lee HL, Lee SW, Han NI, Kim SH, Song MJ, Hwang S, Sung PS, Jang JW, Bae SH, Choi JY, Yoon SK.
    J Viral Hepat; 2018 Oct; 25(10):1189-1196. PubMed ID: 29660199
    [Abstract] [Full Text] [Related]

  • 4. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V, Rete Sicilia Selezione Terapia–HCV (RESIST-HCV).
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [Abstract] [Full Text] [Related]

  • 5. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY, Levy MT, Shackel N, Davison SA, Prakoso E.
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [Abstract] [Full Text] [Related]

  • 6. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
    Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S, French ANRS CO22 Hepather cohort.
    Lancet; 2019 Apr 06; 393(10179):1453-1464. PubMed ID: 30765123
    [Abstract] [Full Text] [Related]

  • 9. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
    Piñero F, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, Anders M, Schinoni MI, Reggiardo V, Palazzo A, Videla M, Alonso C, Santos L, Varón A, Figueroa S, Vistarini C, Adrover R, Fernández N, Perez D, Tanno F, Hernández N, Sixto M, Borzi S, Bruno A, Cocozzella D, Soza A, Descalzi V, Estepo C, Zerega A, de Araujo A, Cheinquer H, Silva M, LALREAN.
    Liver Int; 2019 Jun 06; 39(6):1033-1043. PubMed ID: 30636361
    [Abstract] [Full Text] [Related]

  • 10. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
    Quaranta MG, Cavalletto L, Russo FP, Calvaruso V, Ferrigno L, Zanetto A, Mattioli B, D'Ambrosio R, Panetta V, Brancaccio G, Raimondo G, Brunetto MR, Zignego AL, Coppola C, Iannone A, Biliotti E, Rosselli Del Turco E, Massari M, Licata A, Barbaro F, Persico M, Morisco F, Pompili M, Cerini F, Puoti M, Santantonio T, Craxì A, Kondili LA, Chemello L, On Behalf Of Piter Collaborating Investigators.
    Viruses; 2024 Apr 26; 16(5):. PubMed ID: 38793565
    [Abstract] [Full Text] [Related]

  • 11. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M, Law MG, Valerio H, Grebely J, Amin J, Hajarizadeh B, Selvey C, George J, Dore GJ.
    J Hepatol; 2019 Aug 26; 71(2):281-288. PubMed ID: 31078544
    [Abstract] [Full Text] [Related]

  • 12. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.
    Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M, collaborators.
    Dig Liver Dis; 2019 Feb 26; 51(2):310-317. PubMed ID: 30473220
    [Abstract] [Full Text] [Related]

  • 13. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F, Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver.
    World J Gastroenterol; 2018 Jun 28; 24(24):2582-2595. PubMed ID: 29962815
    [Abstract] [Full Text] [Related]

  • 14. Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents.
    Kao YT, Liu YC, Cheng YT, Wen YW, Hsieh YC, Hsu CE, Su CW, Tai JC, Chen YC, Jeng WJ, Lin CY, Chien RN, Tai DI, Sheen IS.
    Viruses; 2024 Sep 18; 16(9):. PubMed ID: 39339961
    [Abstract] [Full Text] [Related]

  • 15. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    Sangiovanni A, Alimenti E, Gattai R, Filomia R, Parente E, Valenti L, Marzi L, Pellegatta G, Borgia G, Gambato M, Terreni N, Serio I, Belli L, Oliveri F, Maimone S, Brunacci M, D'Ambrosio R, Forzenigo LV, Russo FP, Rumi M, Barone M, Fracanzani AL, Raimondo G, Giannini EG, Brunetto MR, Villa E, Biganzoli E, Colombo M, Lampertico P.
    J Hepatol; 2020 Sep 18; 73(3):593-602. PubMed ID: 32243959
    [Abstract] [Full Text] [Related]

  • 16. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M, Ken A, Okuno T.
    Cancer; 1999 May 01; 85(9):1943-50. PubMed ID: 10223234
    [Abstract] [Full Text] [Related]

  • 17. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.
    Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M.
    J Hepatol; 2019 May 01; 70(5):874-884. PubMed ID: 30684506
    [Abstract] [Full Text] [Related]

  • 18. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
    Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V, Simon T, Abou-Samra AB, Chung RT, Butt AA.
    Hepatology; 2018 Jun 01; 67(6):2244-2253. PubMed ID: 29205416
    [Abstract] [Full Text] [Related]

  • 19. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
    Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A.
    J Hepatol; 2018 Aug 01; 69(2):345-352. PubMed ID: 29551707
    [Abstract] [Full Text] [Related]

  • 20. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
    Degasperi E, Galmozzi E, Pelusi S, D'Ambrosio R, Soffredini R, Borghi M, Perbellini R, Facchetti F, Iavarone M, Sangiovanni A, Valenti L, Lampertico P.
    Hepatology; 2020 Dec 01; 72(6):1912-1923. PubMed ID: 32762045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.